On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics, sold 20,000 shares for approximately $1.7 million, based on an SEC Form 4 filing. This sale is significant compared to Waddill’s historical activity, with no indirect participation. The transaction coincided with strong market performance, as shares were up 123.8% over the prior year. As of Feb. 14, 2026, the stock price was $81.49, with a market capitalization of $5.09 billion and revenue of $209.22 million. Protagonist Therapeutics focuses on rare blood disorders and inflammatory diseases, showing strong growth potential.

At the J.P. Morgan Healthcare Conference in early January 2026, Protagonist highlighted significant growth projections in the next 12-24 months, expanding clinical trials and advancing key pharmaceutical products with support from firms like Johnson & Johnson. The stock soared 123% in 2025, attracting interest from Wall Street and institutional investors. While Waddill’s share sale raises questions, analysts rate the stock a “strong buy” with high growth expectations. Before investing, consider alternative stock options that may offer higher returns based on historical performance and market analysis.

Read more at Yahoo Finance: Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance